Evommune, Inc. (EVMN) is a publicly traded the market company. As of May 21, 2026, EVMN trades at $22.23 with a market cap of $788.44M and a P/E ratio of -1.95. EVMN moved +4.69% today. Year to date, EVMN is +44.96%; over the trailing twelve months it is flat. Its 52-week range spans $13.89 to $33.20. Analyst consensus is strong buy with an average price target of $52.00. Rallies surfaces EVMN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Evommune's Phase 2a Success Drives $65 Price Target and $125M Funding: Evommune's EVO301 Phase 2a trial for atopic dermatitis met primary endpoints, driving shares higher and prompting HC Wainwright to raise its price target from $35 to $65. The company also secured $125 million in a private placement at $27.88 and Oppenheimer initiated coverage with a $42 target.
| Metric | Value |
|---|---|
| Price | $22.23 |
| Market Cap | $788.44M |
| P/E Ratio | -1.95 |
| EPS | $-11.22 |
| Dividend Yield | 0.00% |
| 52-Week High | $33.20 |
| 52-Week Low | $13.89 |
| Volume | 63 |
| Avg Volume | 0 |
| Revenue (TTM) | $13.00M |
| Net Income | $-68.87M |
| Gross Margin | 0.00% |
8 analysts cover EVMN: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $52.00.